CSBR Stock Overview
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.
No risks detected for CSBR from our risk checks.
Champions Oncology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.47|
|52 Week High||US$11.00|
|52 Week Low||US$6.81|
|1 Month Change||22.04%|
|3 Month Change||26.60%|
|1 Year Change||-12.23%|
|3 Year Change||53.24%|
|5 Year Change||196.87%|
|Change since IPO||-21.08%|
Recent News & Updates
Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Champions Oncology press release (NASDAQ:CSBR): Q4 Non-GAAP EPS of -$0.02. Revenue of $12.9M (+21.7% Y/Y).
|CSBR||US Life Sciences||US Market|
Return vs Industry: CSBR exceeded the US Life Sciences industry which returned -19.8% over the past year.
Return vs Market: CSBR underperformed the US Market which returned -10.1% over the past year.
|CSBR Average Weekly Movement||6.8%|
|Life Sciences Industry Average Movement||11.0%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CSBR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CSBR's weekly volatility (7%) has been stable over the past year.
About the Company
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
Champions Oncology Fundamentals Summary
|CSBR fundamental statistics|
Is CSBR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CSBR income statement (TTM)|
|Cost of Revenue||US$23.63m|
Last Reported Earnings
Apr 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.041|
|Net Profit Margin||1.12%|
How did CSBR perform over the long term?See historical performance and comparison
Is CSBR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CSBR?
Other financial metrics that can be useful for relative valuation.
|What is CSBR's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CSBR's PS Ratio compare to its peers?
|CSBR PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
LAB Standard BioTools
HBIO Harvard Bioscience
TKNO Alpha Teknova
CSBR Champions Oncology
Price-To-Sales vs Peers: CSBR is expensive based on its Price-To-Sales Ratio (2.6x) compared to the peer average (2.1x).
Price to Earnings Ratio vs Industry
How does CSBR's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Sales vs Industry: CSBR is good value based on its Price-To-Sales Ratio (2.6x) compared to the US Life Sciences industry average (5x)
Price to Sales Ratio vs Fair Ratio
What is CSBR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.6x|
|Fair PS Ratio||2.1x|
Price-To-Sales vs Fair Ratio: CSBR is expensive based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).
Share Price vs Fair Value
What is the Fair Price of CSBR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CSBR ($9.47) is trading below our estimate of fair value ($31.37)
Significantly Below Fair Value: CSBR is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Champions Oncology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSBR's forecast earnings growth (92% per year) is above the savings rate (1.9%).
Earnings vs Market: CSBR's earnings (92% per year) are forecast to grow faster than the US market (14.4% per year).
High Growth Earnings: CSBR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CSBR's revenue (16.6% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: CSBR's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Champions Oncology performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CSBR has high quality earnings.
Growing Profit Margin: CSBR's current net profit margins (1.1%) are higher than last year (0.9%).
Past Earnings Growth Analysis
Earnings Trend: CSBR has become profitable over the past 5 years, growing earnings by 60.6% per year.
Accelerating Growth: CSBR's earnings growth over the past year (51.4%) is below its 5-year average (60.6% per year).
Earnings vs Industry: CSBR earnings growth over the past year (51.4%) exceeded the Life Sciences industry 15.6%.
Return on Equity
High ROE: CSBR's Return on Equity (6%) is considered low.
Discover strong past performing companies
How is Champions Oncology's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CSBR's short term assets ($19.7M) exceed its short term liabilities ($17.5M).
Long Term Liabilities: CSBR's short term assets ($19.7M) exceed its long term liabilities ($8.8M).
Debt to Equity History and Analysis
Debt Level: CSBR is debt free.
Reducing Debt: CSBR has not had any debt for past 5 years.
Debt Coverage: CSBR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CSBR has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Champions Oncology current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CSBR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CSBR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CSBR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CSBR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CSBR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ronnie Morris (56 yo)
Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017 and its President since 2021. Dr. Morris previously served as the President and a Director of Cha...
CEO Compensation Analysis
Compensation vs Market: Ronnie's total compensation ($USD775.00K) is about average for companies of similar size in the US market ($USD760.00K).
Compensation vs Earnings: Ronnie's compensation has been consistent with company performance over the past year.
Experienced Management: CSBR's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: CSBR's board of directors are seasoned and experienced ( 11.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Champions Oncology, Inc.'s employee growth, exchange listings and data sources
- Name: Champions Oncology, Inc.
- Ticker: CSBR
- Exchange: NasdaqCM
- Founded: 1985
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$128.058m
- Shares outstanding: 13.52m
- Website: https://www.championsoncology.com
Number of Employees
- Champions Oncology, Inc.
- One University Plaza
- Suite 307
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/13 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.